Introduction
The pituitary gland is an endocrine organ producing six hormones (GH, thyroid stimulating hormone, prolactin, adrenocorticotropic hormone, luteinizing hormone and follicle-stimulating hormone). These hormones act throughout the body in other target glands or tissues coordinating physiological steps such as growth, metabolism, lactation, extracellular fluid volume and composition, or reproduction. Specifically differentiated secretory cells produce all hormones. Of these, the most abundant are the somatotrophs (60% of the whole secretory population), which produce growth hormone (GH). Pituitary embryonic development is well studied in animal models and in humans.
Pituitary derives from an upper pharynx group of cells called the Rathke's pouch that migrates backwards and contacts the nervous system. However the regulation of cell renewal after birth, and the secretory cell ability to adapt to huge increases in the body needs for a hormone (for example puberty, pregnancy, hypothyroidism) while maintaining differentiation are unknown (Melmed, 2003; Chesnokova et al., 2008a) . The balance between proliferation, survival and differentiation must be very tight as the pituitary controls essential processes affecting the whole body. It has been proposed that senescence is an essential pathway in the postnatal pituitary that explains the intrinsic benignity of adenomas (Melmed, 2003; Chesnokova et al., 2008a) . Humans and rodents somatotrophs express the RET tyrosine-kinase receptor and its co-receptor GFRa1. RET is a tyrosine kinase receptor activated by the ligand GDNF through heterodimerization with GFRa1 and belongs to the family of dependence receptors together with the netrin receptor, progesterone receptor, or the recently demonstrated TrkA and TrkC (Bordeaux et al., 2000; Goldschneider and Mehlen, 2010; Nikoletopoulou et al., 2010) . In the absence of a ligand, dependence receptors are processed by proteases inducing apoptosis through specific pathways, depending on the receptor and type of cells. In somatotrophs, RET forms a complex with Caspase 3 and PKCd in the cytoplasmic side of the membrane. Once complexed, the three become processed and Caspase 3 and PKCd become active. This induces the binding of cEBPa/CREB to an element of the Pit-1 promoter conserved in mouse, rat and humans with a huge induction of Pit-1 (Canibano et al., 2007; Garcia-Lavandeira et al., 2010) . Pit-1 is an essential transcription factor for embryonic differentiation of pituitary precursors into somatotrophs and postnatal maintenance of the somatotroph phenotype (Castrillo et al., 1991; Pfaffle et al., 1992; Lin et al., 1993; Ward et al., 2006; Solloso et al., 2008) . In a mature somatotroph, an over-the-level increase in the Pit-1 protein expression induces accumulation of p53 and apoptosis. Contrarily, when the ligand GDNF binds to GFRa1 and RET, the receptor dimerizes and crossactivates its tyrosine-kinase activity preventing intracellular processing and inducing p-AKT activation, Pit-1 repression and ultimately somatotroph survival. This appears to be a conserved pathway in rodents and humans (Canibano et al., 2007; Garcia-Lavandeira et al., 2010) .
p53's relationship with apoptosis is well known due to it being a master protein-controlling cell cycle arrest (senescence) and survival/apoptosis of abnormal cells. p53 controls apoptosis via the regulation of genes implicated in cytocrome C release from the mitochondria and acts as a transcriptional activator of deathrelated receptor genes (Vousden, 2000) . Another nontranscriptional-dependent apoptosis occurs when cytosolic p53 directly activates Bax. In other cell types, p53 relocates into the mitochondria and directly binds to the Bcl2 proteins inhibiting the anti-apoptotic and promoting the pro-apoptotic members (Moll et al., 2005) .
One of the main regulators of p53 expression is ARF (p14ARF in humans, p19Arf in rodents), a productisoform 4-of the CDKN2A locus. p19Arf binds and retains in the nucleolus MDM2 the E3-ubiquitin ligase in charge of marking p53 for constant destruction. Thus, when p19Arf is present p53 accumulates (Vousden, 2000) . p19Arf is essential for p53-dependent apoptosis activated by Myc and other oncogenic signals, the so-called oncogenic stress (Palmero et al., 1998; Zindy et al., 1998; de Stanchina et al., 1998) , reviewed in (Gil and Peters, 2006) . However p19Arf-independent stabilization of p53 through post-translational modifications or direct binding occurs in the DNA damage response pathway or by lack of pyrimidine nucleotides (Harris and Levine, 2005; Meek, 2009; Khutornenko et al., 2010) .
In somatotrophs the pathway that led from Pit-1 overexpression to p53 increase remains unknown. This work studied the mechanism that leads from RET processing and Pit-1 increase to p53 accumulation in somatotrophs. We show that Pit-1 is a direct regulator of the p19Arf promoter through a conserved binding site present in the rodent and human gene promoter. p19Arf mRNA and protein expression leads to p53 accumulation and apoptosis. We used a somatotroph cell line, primary pituitary cultures and the whole organ to establish the mechanism's importance in the somatotroph physiology.
Results
The rat somatotroph cell line GH4C1 expresses the ligand GDNF and the GFRa1 co-receptor but does not express the RET receptor. The introduction of short isoform of the RET receptor (RET-S) in this cell line induces a strong expression of Pit-1, accumulation of p53 and apoptosis (Canibano et al., 2007) . To determine whether p19Arf expression could be related to Pit-1 induction and p53 accumulation we made a time-course study of the expression of these proteins in relation with apoptosis. After transfection, GH4C1 cells were maintained in culture medium for 1 day (10% fetal calf serum (FCS)) followed by deprivation (0.1% bovine serum albumin) to get rid of the GDNF present in serum or secreted by the cells. We compared full-length RET-S receptor, RET-S KR -a point-mutant receptor unable to activate the kinase in the presence of GDNF-, IC-RET 707À1017 -the intracellular Caspase-3-processed RET fragment able to directly induce Pit-1 and apoptosis-and exogenous transfection of Pit-1. RET-S reached the peak of apoptosis after 48 h of deprivation, RET-S KR after 24 h whereas IC-RET 707À1017 already induced a strong apoptosis 12 h after deprivation ( Figure 1a ). Through western blots we studied the expression of the proteins implicated in the pathway (Figure 1b) . In correlation to apoptosis, RET-S fully induced Pit-1 and p53 at 48 h whereas RET-S KR only needed 24 h and IC-RET 707À1017 induced a quick and direct enhancement of Pit-1 and p53 expression at 12 h. Exogenous Pit-1 steadily increased apoptosis to reach the peak at 48 h in Pit-1 accumulation, p53 increase and apoptosis (Figures 1a and b) . Any of the three RET receptors or exogenous Pit-1 induced p19Arf expression parallel to Pit-1 and p53 accumulation (Figure 1b) . However, no change was detected in p16 (CDKN2A, isoform 1), a gene codified in the same locus and frequently transcribed in parallel (Figure 1c) , nor in p21Cdkn1a, a p53 gene target in cell cycle. The RET ligand GDNF repressed Pit-1, p19Arf and p53 expression and consequently inhibited the apoptosis induced by RET-S ( Figure 1d ). As expected, GDNF could not suppress Pit-1 and apoptosis induction when exogenous Pit-1 or mutant RET-S KR was present, but p19Arf expression was maintained (Figures 1d and e) . These data suggested a strong temporal relationship between Pit-1 and p19Arf expression.
RET-induced apoptosis was absolutely dependent on p53 increase as it was blocked in the presence of p53 siRNA in spite of Pit-1 or p19Arf increase (Figure 2a ). p19Arf basal levels in cell lines or tissues are considered very low or absent (Vousden, 2000) . RET or Pit-1 transfection increased binding of p19Arf to MDM2 as seen by co-immunoprecipitation (Figure 2b ). If Pit-1-induced p53 accumulation was not mediated by p19Arf it would not need new ARF synthesis as p53 is constantly produced, although degraded by MDM2. Incubation with Cycloheximide, a translational inhibitor, during the last 12 h blocked Pit-1-induced apoptosis suggesting the need for active protein translation, as for example p19Arf (Supplementary Figure S1) . We designed and transcribed specific siRNAs against the exon 1 of rat p19Arf (CDKN2A exon 1b) that did not interfere with p16Cdkn2a encoded in the same locus but starting in an alternative first exon (CDKN2A exon 1a). In the presence of p19Arf siRNA but not GFP siRNA, the increase in Pit-1 induced by RET-S (Figure 2c ), RET-S KR (Figure 2d ), IC-RET (Figure 2e ) or Pit-1 (Figure 2f ) was not affected. However, p19Arf protein expression was reduced, p53 did not accumulate and the apoptosis was significantly blocked. These experiments demonstrate the absolute requirement of p19Arf for RET/Pit-1-induced apoptosis in somatotrophs.
Next we studied the mechanism through which Pit-1 was able to induce p19Arf expression. The low basal levels of p19Arf (p14ARF) explain that its expression is commonly regulated through transcriptional activation (Bates et al., 1998; Robertson and Jones, 1998; de Stanchina et al., 1998; Inoue et al., 1999; del Arroyo et al., 2007; Taneja et al., 2010) . However, ARF expression also could be regulated through proteasomal inhibition (Kuo et al., 2004; Chen et al., 2010) . We quantified Pit-1 and p19Arf mRNA transcription by quantitative reverse transcriptase PCR. At 12 h after deprivation, RET-S induced a twofold increase in Pit-1 mRNA, but p19Arf mRNA was not induced until 24 h (Figures 1a and 3a) . As expected, Pit-1 transfection induced a strong and progressive increase in Pit-1 mRNA expression. Again p19Arf mRNA presented a parallel but delayed increase in correlation with Pit-1 protein accumulation (Figure 3b ). These results demonstrating a tight delayed parallelism between Pit-1 mRNA and p19Arf mRNA led us to search for transcriptional pathways that regulated p19Arf gene expression.
Many proteins regulate p19Arf expression but few transcription factors have been demonstrated as directly Figure 1 p19Arf expression, but not p16Cdkn2a, correlates with RET-induced Pit-1 expression, p53 increase and apoptosis in somatotroph GH4C1 cells. (a) Time course of apoptosis in cells transfected with wild-type RET-S, kinase-dead point mutant RET-S KR , intracellular RET fragment IC-RET 707À1017 , Pit-1 or empty vector (Rc). Cells were allowed to seed during 24 h followed by serum deprivation. (b) Time course of protein expression as measured by western blot against RET short isoform (RET-S), Pit-1, p19Arf and p53. Tubulin is shown as a loading control. IC-RET 707À1017 was detected with an antibody directed to an intracellular epitope (RETcI). (c) Expression of p16Ink4a or p21Cdkn1a does not increase after RET-S or Pit-1 transfection. (d) Addition of rGDNF (100 ng/ml), the RET ligand, prevents RET-induced apoptosis and also the increase in Pit-1, p19Arf and p53 in RET-Stransfected cells but not in cells transfected with Pit-1 or RET-S KR (e). ***Pp0.005; **Pp0.01.
binding a DNA response element in the p19Arf promoter regulating its transcription. p53 may directly repress p19Arf promoter (Robertson and Jones, 1998) . E2F1 increases p19Arf expression (Bates et al., 1998; del Arroyo et al., 2007) . Dmp1 has been demonstrated to bind and activate the mouse p19Arf promoter (Inoue et al., 1999 ) (see Supplementary Figure S2 ). The expression of the RET family proteins and the pathway RET/cEBPa/Pit-1/p53/apoptosis is conserved from rodents to humans (Urbano et al., 2000; Japon et al., 2002; Canibano et al., 2007) and Diaz-Rodriguez unpublished results). To understand whether a link connecting Pit-1 excess with p19Arf gene expression is also conserved, we made an 'in silico' study of the locus in the human chromosome 9p21 where the p14ARF gene is localized and compared it with the same locus in mice 4C3-C6 and rats 5q32 ( Figure 4a ). CDKN2A is a complex gene that generates two different proteins, p14ARFCD-KN2A (in rodents p19ArfCdkn2A) and p16CDKN2A, through alternative transcription of a different first exon (exon 1b or exon 1a) with displaced reading frame of the second and third common exons. A few kb before the start of CDKN2A ends the CDKN2B gene (p15CDKN2B). The organization of the locus, CDKN2A and B genes is identical in humans (9p21), rats (5q32) and mice (4C1-C3). A new gene in this locus was recently discovered. The CDKN2BAS gene (Pasmant et al., 2007) , also called ANRIL, is a long non-proteincoding RNA with 19 exons and is transcribed in the contrary direction to CDKN2A, overlapping the CDKN2B gene in the opposite strand and further on. CDKN2BAS first exon coincides within the opposite strand of the p19Arf promoter as the þ 1 transcriptional initiation site starts only À303 bp before p19Arf þ 1 transcriptional initiation site. In rodents this new CDKN2BAS gene within the locus is yet to been described. We compared in detail the 5 0 region of the human ARF gene from humans, mice and rats using PROMO and Clustal W2 (Supplementary Figure S2) . When comparing a region of À1200 bp from the ARF þ 1 transcriptional initiation site there was a homology of 86% between rats and mice but the homology of either rodent species with humans was reduced to 30%. Comparing the first À600 bp, from the p19Arf þ 1transcriptional initiation site to the end of the first exon of CDKN2BAS/ANRIL the homology between rodents was 90% but the homology between rodents and humans grew to 50%. As the RET singular expression in somatotrophs is conserved in mice, rats and humans, and the RET/Pit-1 apoptotic pathway is preserved, we looked for common response elements to the three species. We found DNA conserved response elements for p53, E2F1, DMP1/ETS-slightly displaced over the previously described in mouse-, AP2 and PAX. Interestingly, we found a long sequence (15 bp) that included a high scored Pit-1-binding site (ATTGG). The sequence was identical in humans and rodents (mice and rats) CDKN2A/ARF promoters although displaced a few bases (À515 to À499 vs À464 to À448) (Figure 4a and Supplementary Figure S2 ). Within the three promoters there were other putative Pit-1-binding sites but they scored much lower and were not common to the three species.
To test for the presence of a Pit-1 responsive element in the p19Arf promoter we used a construct bearing À1115 bp from the mouse p19Arf promoter cloned in front of luciferase and tested if RET or Pit-1 could induce luciferase activity. As seen in Figure 4b , either the RET-S receptor or Pit-1 induced a progressive activity of this p19Arf promoter reaching five times over the control at 24 h. The fragment IC-RET 707-1017 induced a faster and stronger activity of the p19Arf promoter in correlation with the faster and stronger activation of Pit-1. GDNF blocked p19Arf promoter expression induced by RET-S but not by Pit-1 (Figure 4c ).
To understand if the endogenous ARF promoter of the GH4C1 somatotrophs was similarly activated by Pit-1, we performed a chromatin immunoprecipitation with Pit-1 antibody or non-immune rabbit immunoglobulin G (a-IgG) followed by amplification of a 102-bp band that included the Pit-1-binding element (Figure 4a ). With RET-S transfection there was a specific band after the immunoprecipitation of Pit-1 that was not present in cells transfected with an empty vector or in RET-S-transfected cells immunoprecipitated with IgG (Figure 4d ). The same band was obtained after Pit-1 transfection. When the cells were transfected with IC-RET 707À1017 a strong band was obtained earlier, 6 h, when no band could be clearly seen in Pit-1-transfected cells yet. Quantitative PCR confirmed the results.
The majority of the studies in p19Arf protein expression are performed in cancer cell lines or mouse embryonic fibroblasts. We wanted to see if we obtained similar results in a more physiological system as rat primary pituitary cultures. In our primary pituitary cultures the high proportion (60%) of somatotrophs is maintained (Coya et al., 1999; Garcia et al., 2001; Canibano et al., 2007) . Serum (FCS) contains some GDNF and somatotrophs secrete GDNF when cultured in full medium (10% FCS). Serum deprivation (namely GDNF deprivation) induced a strong apoptosis that was blocked in the presence of GDNF (Figure 5a ). Apoptosis was prevented in the presence of RET siRNA or Pit siRNA and in correlation with the data in GH4C1, the presence of p19Arf siRNA blocked RETinduced apoptosis. In Figure 5b the correspondent protein levels are shown. Both RET-S and RET-L isoforms are expressed in somatotrophs. Serum deprivation activates the intracellular processing of RET characteristic of dependence receptors, as seen by the low molecular weight bands (intracellular caspase processed RET receptor (aa 707-1017) (RET-IC)). This was accompanied by a strong induction of Pit-1 expression, p19Arf increase and p53 accumulation (and apoptosis). p53 appears as a group of bands suggesting that the protein can be in anyway modified.
In the presence of GDNF, full-length RET becomes phosphorylated (p-Y1062-RET, pRET, Figure 5c ) and intracellular processing is greatly reduced. Therefore neither Pit-1, p19Arf or p53 proteins increase, with survival being the end result (Figure 5b ). Reducing RET protein expression with RET siRNA also prevented RET processing and the increase in Pit-1, p19Arf or p53. Reducing Pit-1 levels did not prevent intracellular RET processing as expected, but effectively blocked p19Arf or p53 increase. Finally, reducing p19Arf levels did not prevent RET processing or Pit-1 increase, but prevented p53 accumulation (and apoptosis). These results confirmed the direct pathway between RET processing, Pit-1 and p19Arf expression and its inhibition when the ligand GDNF is present.
Next we wanted to evaluate the pathway in the entire pituitary gland. It is assumed that the basal level of p19Arf expression in adult normal tissues is very low or absent. However, there are not detailed studies of p19Arf protein expression and localization in the body organs in physiological conditions. We found one single immune detection picture of ARF in normal adult human anterior pituitary (AP) (Kirsch et al., 2009 ) and none in rodents. As seen in Figure 5b , untreated primary pituitary cultures had low but detectable p19Arf protein expression, although this could be induced through establishing the primary culture. We performed a western blot with young adult AP extracts (60 days) and compared with the GH3 (somato-lactotroph) and GH4C1 (somatotroph) pituitary cell lines (Figure 6a ). There was detectable p19Arf expression in the AP gland and less in the pituitary cell lines. RET-S expression was detected exclusively in the AP but not in the cell lines (Urbano et al., 2000; Japon et al., 2002; Canibano et al., 2007) . A high proportion of the total RET was tyrosine phosphorylated (pRET) indicating kinase activity corresponding with the elevated expression of GDNF present in the AP but also in the cell lines.
To explore the level of activation of the pathway in normal pituitary we performed immunohistochemistry in coronal sections of adult rat pituitary (Figure 6b and Supplementary Table S1a). p19Arf was detected Figure 4 Pit-1 directly binds and activates the p19Arf promoter through a Pit-1-binding element conserved in human, mouse and rat. (a) Diagram representing the CDKN2 locus where three genes-CDKN2A, CDKN2B and CDKN2BAS or ANRIL-are localized. The CDKN2A gene expresses two mRNAs: ARF (white boxes: exon 1b, exon 2 and exon 3) and p16 (gray boxes: exon 1a, displaced reading frame of exon 2 and exon 3). ARF promoter overlaps CDKN2BAS first exon as both genes are oriented in opposite senses. Figure S2) reveals an identical region of 15 bp with a consensus binding element for Pit-1. (b) RET-S induces a progressive induction of the mouse p19Arf promoter luciferase expression, reaching five times increase over the control (Rc) 24 h after deprivation. Pit-1 was a even more potent activating p19Arf promoter. IC-RET707À1017 induces a fast and huge activation of the p19Arf promoter (40 times over the control) in correlation with its strong ability to increase Pit-1 expression. (c) GDNF blocks RET-S but not Pit-1 activation of the p19Arf promoter. (d) Chromatin immunoprecipitation against Pit-1 or control rabbit immunoglobulin G followed by PCR amplification of the endogenous Pit-1 element of the p19Arf promoter (showed by arrows in a). At 24 h after deprivation, RET-S or exogenous Pit-1 transfection induce binding of the Pit-1 transcription factor to this region. However, IC-RET 707À1017 induces a faster binding of Pit-1 transcription factor (6 h) in correlation with its faster ability to increase Pit-1, p53 and apoptosis. ***Pp0.005; **Pp0.01; *Pp0.05. exclusively in the AP and there was no staining in the intermediate lobe (IL) or neuropituitary. p19Arf positivity was dependent upon the area studied (see Supplementary Table S1a ). There was a higher proportion (30%) near the marginal zone where the GPS niche of stem cells is localized, but a lower proportion (15%) was isolated cells interspersed in the lobes, mainly at the periphery. In high magnification, some p19Arf þ cells appear with an empty nucleus and cytoplasmic staining whereas the peripheral ones appear as whole stained cells with positive cytoplasm and nucleus. Our p19Arf staining was similar to the pituitary microphotograph previously published using a different antibody (Kirsch et al., 2009; Supplementary Figures) . Pit-1 (80%) and somatotrophs (GH, 60%) were the most abundant secretory cells and were concentrated in the central and lateral sides of the AP lobes (Japon et al., 1994) . pRET staining (66%) was marked in the periphery of AP lobes coincident with the GH area. Full-length RET (RETc) stained the AP lobes (60%). The neuropituitary was also stained in correlation with described RET expression (Urbano et al., 2000; Garcia-Lavandeira et al., 2009 ). In the AP, pRET marked precisely the plasma membrane of the cells whereas RETc stained whole cytoplasm with some membrane reinforcement. Active-Caspase 3 staining, a possible indicator of apoptosis, was present in a few isolated cells of the AP (6%). Nuclear p53 staining in the AP pituitary was present in low intensity in 15% of AP cells, but intense nuclei were scarce (5%). Similarly, Ki67 staining was also low (4%). The percentage of positive ARF and p53 were coincident. The percentage of intense p53 (apoptosis) and Ki-67 (proliferation) were coincident.
Comparison of ARF promoter sequences in the three species (Supplementary
We hypothesized that as the somatotrophs were the 60% of the secretory mass in an adult pituitary and the renewal was low we could expect a detectable but low percentage of somatotrophs that were p19Arf þ . Double positives were investigated by performing double immunofluorescences in coronal sections of the pituitary focusing on the AP lobes (somatotroph areas) (Figures 6c-e and Supplementary Table S1b). Double staining for p19Arf/Pit-1 revealed a high number of p19Arf þ cells negative for Pit-1. However, 2.6% of the Pit-1 cells were double p19Arf þ /Pit-1 þ (Figure 6c ). Double positives presented either nucleolar p19Arf or nucleolar and cytoplasmic p19Arf. In some cells the chromatin seemed condensed (micronuclei) with low DAPI and Pit-1 nuclear staining suggesting apoptotic cells. We performed triple staining of Pit-1, p19Arf and TUNEL (Figure 6d ). Practically all TUNEL-positive cells were also Pit-1 and p19Arf triple positives. Double staining for p19Arf/GH revealed a similar picture (Figure 6e ): few double positive cells with blended yellow color (4.3%). As GH was stored in the endoplasmic reticulum whereas cytoplasmic p19Arf was concentrated in the mitochondria, in some somatotrophs there was regional staining in the same cell.
Somatotrophs express GDNF and the co-receptor GFRa1 (Urbano et al., 2000; Japon et al., 2002) . If our hypothesis was correct, the majority of somatotrophs would respond to GDNF activating RET as a tyrosine kinase to control the levels of Pit-1 and therefore survive. Double staining for GH and pRET revealed that near all somatotrophs presented a strong positivity in the plasma membrane (Figure 6c ). We believe that pRET activation in the somatotrophs explained the low percentage of somatotrophs positive for p19Arf. In a normal pituitary gland, only a few somatotrophs are unable to maintain pRET activation and RET is processed and the sequence of apoptotic events initiated.
In summary, the RET/Pit-1/p19Arf/p53 pathway in somatotrophs relates dependence receptors (RET expression) with differentiation (Pit-1 expression), functional activity (GH expression), senescence (growth arrest) and survival/death. This pathway could be altered in diseasecausing somatotroph hyperplasia/adenomas (gigantism and acromegalia) or in hypoplasia (pituitary dwarfism). Alteration of this delicate balance could cause excess of somatotroph death leading to dwarfism whereas resistance to it could cause adenomas. Cultures (containing 60% of somatotrophs) were transfected with control GFP, RET, Pit-1 or p19Arf siRNAs. The cultures were maintained in full medium (10%FCS) or deprived in the absence or presence of GDNF (100 ng/ml) and apoptosis was measured (a) or extracts were obtained and studied by western blot (b). GDNF prevents RET intracellular processing as shown by the smaller molecular weight bands (RET-IC, 70 kD to 40 kD). GDNF and RET or Pit siRNA reduce Pit-1 and consequently p19Arf and p53 expression blocking apoptosis. p19Arf siRNA does not prevent RET processing or Pit-1 expression but blocks p53 increase and thus, also blocks apoptosis. (c) Fast RET tyrosine kinase phosphorylation induced by GDNF (30 min) as detected by the specific antibody anti-p-Y 1062 -RET (pRET) (***Pp0.005).
RET and Pit-1 induce p19Arf promoter in somatotrophs E Diaz-Rodriguez et al Figure 6 The RET/Pit-1/p19Arf pathway is present in the somatotrophs of the young adult pituitary but is maintained at low levels because of constant GDNF-induced RET tyrosine-kinase phosphorylation. 
Discussion
The physiological renewal of secretory cells in the adult mammal pituitary is not well defined. Contrarily, embryonic commitment and differentiation of precursors is much better understood (recently reviewed (Davis et al., 2010) ). It is known that after birth pituitary maintains cell renewal and adapts to physiological changes such as puberty or pregnancy. We focused our study on pituitary-differentiated somatotrophs (GH).
Pit-1 overexpression induces p19Arf expression: the link of dependence receptors with OIA Somatotrophs account for the majority of secretory cells in the AP even after puberty. They express the RET/ GFRa1 receptors and, in the absence of GDNF, RET processing led to apoptosis through Pit-1 overexpression and p53 induction (Canibano et al., 2007) . This work explains how excess Pit-1 binds and induces directly p19Arf promoter activation and expression. The binding site is conserved through mammal species indicating an important pathway linking differentiation, senescence and apoptosis. p19Arf is codified in the CDKN2A gene that resides in a complex locus, where the promoter of one gene overlaps with exons of a different gene. The organization of the Cdkn2 locus is conserved from humans to rodents revealing the importance of this peculiar order. Many of the studies on CDKN2A expression demonstrate a common regulation for ARF and p16Cdkn2a. However, in somatotrophs p19Arf is exclusively regulated by Pit-1 whereas p16Cdkn2a remains invariable. In general CDKN2A/p19Arf expression is regulated by two main pathways: oncogenes such as Ras and Myc in the so-called oncogene-induced senescence (OIS) or apoptosis (OIA), and DNA damage (Evan and d'Adda di Fagagna, 2009) . We propose that the direct induction of p19Arf promoter by Pit-1 could be classified as OIA although Pit-1 is not an oncogene; but in a somatotroph Pit-1 is required to proliferate (Castrillo et al., 1991; Solloso et al., 2008) . Thus, somatotrophs are protected against excessive proliferation through this RET/Pit-1/p19Arf pathway. Most studies on p19Arf molecular function were performed in cancer cell lines, embryonic fibroblasts (MEFs) or in mouse oncogene-induced tumors and we are uncertain if they are applicable to non-tumor specialized epithelial cells such as somatotrophs. p19Arf has been implicated in three different actions related to tumor suppression: 1-senescence-namely cell cycle arrest and aging promotion-through p53 accumulation, by sequestration of MDM2 in the nucleoli preventing p53 degradation, which induces p21Cip (Cdkn1a) as it happens in MEFs; 2-p53-dependent apoptosis through again p53 accumulation; and 3-direct apoptosis induction through localization in the mitochondria promoting caspase activation (Vousden, 2000; Junttila and Evan, 2009; Chen et al., 2010; Kovi et al., 2010) . In the somatotroph cell line and in the primary pituitary cultures p19Arf increased as p53 and apoptosis increased. Apoptosis was blocked by p19Arf siRNA indicating a straight link between the pathway and somatotroph apoptosis. Two other dependence receptors have been related with p53. UNC5H2 (UNC5B) and UNC5H4 in the absence of its ligand, Netrin, are processed and mediate p53-dependent apoptosis (Tanikawa et al., 2003; Wang et al., 2008) . The mechanism demonstrating how UNC5H2 induces apoptosis through DAP kinase activation has been recently revealed (Guenebeaud et al., 2010) . Interestingly, some years ago it has been demonstrated that DAP kinase induces apoptosis through p19Arf/ p53 (Raveh et al., 2001) . Thus, p19Arf activation could be a common pathway for different dependence receptors. p19Arf promoter overlaps with CDKN2BAS first exon (while conversely, CDKN2BAS promoter overlaps with p19Arf exon 1b). CDKN2BAS codifies a long noncoding RNA that binds polycomb proteins increasing its affinity for CDKN2A chromatin and fully repressing both p19Arf and p16 transcripts (Yap et al., 2010) . It has been described that ANRIL polymorphisms are related to some human diseases such as heart disease, arthritis or colon cancer (Pasmant et al., 2007; Cunnington et al., 2010) . Future experiments will determine if there is a counter regulation of ANRIL and p19Arf in somatotrophs and if ANRIL mRNA levels are altered in somatotroph adenomas.
ARF in the adenopituitary gland
The pituitary gland has two types of p19Arf-stained cells. The Pit-1 negative cells with an intense cytoplasmic p19Arf staining did not have an apoptotic appearance. In these cells p19Arf could be related to quiescence (arrested proliferation) and not senescence/apoptosis, a difference that recent publications locate in the intensity of p19Arf/p53 activation: maximal intensity is related with quiescence whereas moderate p19Arf/p53 activation is related with senescence (Leontieva et al., 2010; Serrano, 2010) . However, in the few p19Arf þ /Pit-1 þ or p19Arf þ /GH þ cells present in the young adult adenopituitary some cells presented condensed chromatin or micronuclei compatible with apoptosis. Practically all of the TUNEL-positive cells were triple positives for Pit-1 and p19Arf. The p19Arf staining in somatotrophs was compatible with both nucleolar function and mitochondrial localization. Coincidentally, when p19Arf is expressed and p53 accumulates, p53 also locates in the mitochondria to mediate apoptosis (Itahana and Zhang, 2008) . The intriguing possibility exists that both p19Arf and p53 could transfer to the mitochondria in parallel.
We saw few somatotrophs (Pit-1 þ or GH þ ) in young adult AP positive for p19Arf whereas the majority presents a strong GDNF-induced RET tyrosine kinase activation. This would lead to reduced Pit-1 and consequently contained GH expression. The balance between pRET/ AKT/low Pit-1 vs processed RET/high Pit-1/p19Arf so favorable to pRET in young AP could be shifted in aged somatotrophs that do not work properly. One interesting future study is determining if age influences the number of somatotrophs-expressing p19Arf explaining the decline in GH related with age.
Pituitary tumors are consistently benign adenomas with only few cases described as pituitary carcinomas. This is even more striking for somatotroph tumors as they are by far the most abundant secretory type of cell in the normal adenopituitary and represents only a 10-15% of pituitary adenomas and 9% of the pituitary carcinomas (Colao et al., 2010) . Somatotroph adenomas maintain RET/Pit-1 expression (Japon et al., 2002) . Again, this suggests that a protective pathway specially controlling the number of somatotrophs will tightly be in command of GH, the most broadly acting hormone of the AP affecting practically all body tissues. Intrinsic senescence of the pituitary secretory cells regulated by the oncogene PTTG was proposed to explain the lack of malignant evolution of the pituitary adenomas. Again, PTTG-dependent senescence pathway seems to affect specially to somatotroph adenomas (Chesnokova et al., 2008b) .
Genetically modified mouse models affecting senescence pathways have not been very useful to study human adenopituitary tumorogenesis as they include combinations with the heterozygous Rb þ /À mouse, which die quickly from big melanotroph tumors in the IL. Interestingly, when development of IL tumors is prevented, a strong phenotype of tumors in the AP unveils (Zhou et al., 2005) . As p19Arf deletion exacerbates Rb deletion-induced IL tumorogenesis (Tsai et al., 2002) , it is possible that p19Arf loss also exacerbate AP tumorogenesis in gonadotrophs, thyrotrophs and somatotrophs. However, neither p53 nor p19Arf was mutated in the few studies including human somatotroph adenomas. Furthermore p19Arf promoter is not methylated in somatotroph pituitary adenomas (Herman et al., 1993; Kirsch et al., 2009) . Other genes could deregulate the RET/Pit-1/p19Arf/p53 pathway in the adenomas. PTTG is an oncogene implicated in pituitary tumorogenesis whose deletion reduces IL tumors in mice (Chesnokova et al., 2005) . Interestingly, PTTG is overexpressed in pituitary adenomas including all somatotropinomas (Zhang et al., 1999) . But PTTG null mice have a hypoplastic pituitary due to senescence with p19Arf/p53/p21 overexpression, especially in somatotrophs (Chesnokova et al., 2007) .
The low mitotic index present in somatotrophs (even in the adenomas) and the strong RET/Pit-1/ARF death/ survival pathway to which they are submitted would explain the absence of p19Arf/p53 mutations in somatotroph adenomas. However, repression of p19Arf mRNA levels through PTTG, ANRIL and other genes seems plausible and should be studied in detail.
In summary, RET/Pit-1/p19Arf/p53 against GDNF/ pRET/AKT pathway is the key link explaining the balance between the need of somatotrophs during the whole postnatal life for their physiological function (GH secretion) and the tight control maintained both on the number of total somatotrophs and the GH hormone production per somatotroph. This tight control is needed to control body size, cell growth and metabolic stability (van Beek et al., 2010; Clayton et al., 2011) . This somatotroph-specific control explains the low number of somatotroph adenomas in comparison with other secretory pituitary adenomas in spite of being the most abundant type of cell.
Materials and methods
Somatotroph cell line culture and transfection Rat GH4C1 pituitary cells were cultured in Dulbecco'smodified Eagle's medium plus 10% FCS. Transfection was performed with Amaxa . Cells were seeded in full medium. The following day cells were washed and cultured in Dulbecco's-modified Eagle's medium þ 0.1% bovine serum albumin (high-grade BSA, Sigma, Madrid, Spain) for 24 to 48 h with/without rat GDNF (100 ng/ml, Sigma) in PBS. To prevent protein translation we used Cycloheximide (23 mg/ml, Sigma) or vehicle (0.3% ethanol). Apoptosis was detected by Hoechst staining as described (Canibano et al., 2007) . We have similar percentages with annexin V or flow cytometry (Bravo et al., 2003) .
Primary pituitary culture
Animal experiments were approved by the USC Ethical Committee and procedures are approved by the animal welfare committee of the Xunta de Galicia. Pituitary cells were cultured in conditioned medium as described (see Supplementary Methods) (Coya et al., 1999; Garcia et al., 2001; Canibano et al., 2007) . To induce apoptosis, the medium was changed to Dulbecco's-modified Eagle's medium plus 0.5% FCS for 36 h.
Interference siRNAs ARF, Pit-1, Ret and GFP siRNAs were made with the Silencer kit (Ambion, Madrid, Spain) using T7-transcribed doublestrand RNA, following the manufacturer's instructions. See Supplementary Methods for details.
Immunodetection
Cell extracts were obtained with Triton lysis buffer as described (Carneiro et al., 1998) or with hot SDS, then diluted with Triton lysis buffer (Garcia et al., 2001; Canibano et al., 2007) . Rat pituitaries were obtained as described (GarciaLavandeira et al., 2010) . Detailed procedures and a list of antibodies are detailed in Supplementary Methods. C-terminal RET antibodies (Santa Cruz, Heidelberg, Germany) were RET C19, against the short RET isoform (RET-S), and RET C20, against the long isoform (RET-L).
DNA sequences of CDKN2A locus
The sequences were found in the following: Homo sapiens NCBI Ref Seq NG_007485.1 (reviewed 29 November 2010); Mus musculus NCBI NC_000070.5, GeneID 12578 (updated 26 Nov 2010); Rattus norvegicus Alternate assembly (Rn_Celera) AC_000073.1. To compare the promoters we used ClustalW c2.0 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) and PROMO (ALGGEN) that generates matrices based in TRANSFAC 8.3 (http://alggen.lsi.upc.es/).
Chromatin immunoprecipitations
Cells were fixed by adding PAF to the medium (1% end concentration) at 37 1C for 10 min followed by addition of glycine (end concentration 0.1 M) for 5 min at room temperature. The procedure is detailed in Supplementary Methods and Canibano et al. (2007) . Quantitative PCR was performed with SybrGreen in an Abyprism 7500 (Applied Biosystems, Madrid, Spain).
